Evidence map›Paper›PMID 39522611›Full record

ArticleMucosal immunology2025

Activation of α2B/2C adrenergic receptor ameliorates ocular surface inflammation through enhancing regulatory T cell function.

Nai-Wen Fan, Man Yu, Shudan Wang, Tomas Blanco, Zala Luznik, Sunil K Chauhan, Veena Viswanath, Daniel Gil, Katherine Held, Yihe Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mucosal immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nai-Wen FanSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA; Department of Ophthalmology, Taipei Veterans General Hospital, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Man YuSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA; Department of Ophthalmology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, PR China.
Shudan WangSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.
Tomas BlancoSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.
Zala LuznikSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.
Sunil K ChauhanSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.
Veena Viswanath(Former) Development Sciences, AbbVie Inc., Irvine, CA 92612, USA.
Daniel Gil(Former) Biological Research, Allergan plc, Irvine, CA 92612, USA.
Katherine HeldOphthalmology Discovery Research, AbbVie Inc., Irvine, CA 92612, USA.
Yihe ChenSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA. Electronic address: yihe_chen@meei.harvard.edu.
Reza DanaSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA. Electronic address: reza_dana@meei.harvard.edu.

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Immunopathogenic Mechanisms of Dry Eye DiseaseR01EY020889 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Reza Dana · 2010 to 2026
$7.9M
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY020889
6 · The paper itself

Abstract

There is an unmet need for effectively treating dry eye disease (DED), a T cell-mediated chronic, inflammatory ocular surface disorder. Given the potential of nonneuronal adrenergic system in modulating T cell response, we herein investigated the therapeutic efficacy and the underlying mechanisms of a specific alpha 2 adrenergic receptor agonist (AGN-762, selective for α2B/2C receptor subtypes) in a mouse model of DED. Experimental DED was treated with the AGN-762 by oral gavage, either at disease induction or after disease establishment, and showed sustained amelioration, along with reduced expression of DED-pathogenic cytokines in ocular surface tissues, decreased corneal MHC-II

Indexed as

Adrenergic alpha-2 Receptor AgonistsDry Eye SyndromesReceptors, Adrenergic, alpha-2Th17 CellsT-Lymphocytes, RegulatoryAnimalsCells, CulturedCytokinesDisease Models, AnimalHumansInflammationMiceMice, Inbred C57BLMice, KnockoutAdrenergic alpha-2 Receptor AgonistsCytokinesReceptors, Adrenergic, alpha-2

Identifiers

PMID39522611
PMCPMC11869812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.